Table 1.

Demographic and clinical characteristics of participants who completed 12 and/or 24 weeks of the study (n = 40^a)

	n	%
Demographic characteristics
Age, years
40–49	7	17.5
50–59	15	37.5
60–69	12	27.5
≥70	7	17.5
Race
Non-Hispanic white	17	42.5
Hispanic	16	40
Black	6	15
Asian	1	2.5
Education
<HS grad	5	12.5
GED/HS grad	8	20
Associate/some college	9	22.5
College degree	7	17.5
Master/doctorate	11	27.5
Marital status
Married	24	60
Single/divorced	13	32.5
Widowed	3	7.5
Clinical characteristics
BMI, kg/m2
<18.5	1	2.5
18.5–24.9	10	25
25–29.9	15	37.5
30–34.9	9	22.5
≥35	5	12.5
Years since diagnosis
<2 years	12	30
2–5	21	52.5
≥5 years	7	17.5
Stage at diagnosis
I	21	52.5
II	17	42.5
III	2	5.0
Her2/neu-positive	4	15
Received chemotherapy	23	57.5
Type of aromatase inhibitor
Anastrozole/Arimadex	35	87.5
Exemestane/Aromasin	3	7.5
Letrozole/Femara	2	5.0
Prior tamoxifen therapy	10	25.0
Prior HRT	6	15.0
Baseline joint conditions	23	57.5
Typeb
Osteoarthritis	14	35.0
Chronic low back pain	2	5.0
Rheumatoid arthritis	1	2.5
Joint surgery	5	12.5
Other	3	7.5

^aData included for 40 participants who provided follow-up data at 12 and/or 24 weeks, out of 53 participants who enrolled in the study

^bCategories not mutually exclusive